EL 921
Latest Information Update: 27 Nov 1995
At a glance
- Originator Pierre Fabre Italia
- Class
- Mechanism of Action Angiogenesis modulating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 27 Nov 1995 Discontinued-Preclinical for Skin disorders in Italy (Unknown route)
- 25 Oct 1994 Preclinical development for Skin disorders in Italy (Unknown route)